EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, BYSI: Beyondspring Inc

23 Oct 25 15:59
LAST:

2.020

CHANGE:
 0.02		OPEN:
2.100		HIGH:
2.100		ASK:
0.010		VOLUME:
20.8K
CHG(%):
0.98		PREV:
2.040		LOW:
1.710		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
23 Oct 252.1002.1001.7102.02020.8K
22 Oct 252.4002.4001.9902.04067.6K
21 Oct 251.6902.2501.6902.200267.8K
20 Oct 251.7701.7701.6801.7407.2K
17 Oct 251.8001.8001.7201.77084.0K
16 Oct 251.7211.8001.6201.785120.6K
15 Oct 251.6001.7201.6001.65049.8K
14 Oct 251.7001.7031.6201.64044.3K
13 Oct 251.7401.7601.6901.710133.1K
10 Oct 251.8301.8501.7301.74018.0K

COMPANY PROFILE

Name:Beyondspring Inc
About:BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Sector:Healthcare
Industry:Biotechnology
Address:100 Campus Drive, Florham Park, NJ, United States, 07932
Website:https://beyondspringpharma.com
CUSIP:G10830100
CIK:0001677940
ISIN:KYG108301006
FIGI:BBG00F9YLST6

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:1.953.4%
MA10:1.8310.4%
MA20:1.8012.1%
MA50:1.8111.4%
MA100:2.051.6%
MA200:1.849.7%
STO9:50.00
STO14:50.00
RSI14:62.62 
WPR14:-32.14
MTM14:0.24
ROC14:0.13 
ATR:0.17 
Week High:2.4018.8%
Week Low:1.6224.7%
Month High:2.4018.8%
Month Low:1.609.7%
Year High:3.4470.3%
Year Low:0.98106.1%
Volatility:41.36